HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fragrance Industry Focused On IP Protection, Possible TSCA Reform

This article was originally published in The Rose Sheet

Executive Summary

Attendees and panelists at the International Fragrance Association North America’s annual business meeting identified key issues facing the industry, including intellectual-property protection, potential reforms to U.S. chemicals law and sustainability,

You may also be interested in...



IFRA North America Gears Up For “Active” Year On Legislative Front

Jennifer Abril, president of International Fragrance Association North America, identifies top priorities for the group in what is expected to be an active year for legislative and regulatory efforts impacting fragrance.

Chemical Safety Improvement Act Promises Stronger EPA Oversight

Introduced by New Jersey Sen. Frank Lautenberg, the Chemical Safety Improvement Act of 2013 would give EPA authority to evaluate chemicals in commerce based on risk to human health and the environment and take action on those deemed unsafe. The bill would update the current Toxic Substances Control Act and potentially impact manufacturers of cosmetic ingredients.

IFRA Report To EC Addresses Trade Secrets, Dangers Of Full Disclosure

Safeguarding trade secrets “remains the most practical and efficient means of protecting the intangible assets” produced by innovation in the fragrance industry, IFRA asserts in a recently issued report. Threats to the industry’s intellectual property, including calls for full disclosure of formulas, put the market at risk, the group says.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel